Low THC vape in the UK is best known for combining CBD with trace THC. But hemp holds far more. Emerging cannabinoids like CBG, CBC, CBN, and THCV are beginning to shape new formulations that expand wellness potential without breaking legal limits.
When people think of hemp-derived vapes, two compounds come to mind: CBD and THC. Yet the hemp plant produces more than a hundred cannabinoids. Most exist in small quantities, and thus they are generally called “minor cannabinoids.”
In recent years, advances in extraction and refinement have made these molecules easier to isolate and study. The result is a new frontier for low THC vape formulations: blends that move past the simple CBD-plus-trace-THC model and instead offer a broader spectrum of plant chemistry.
Cannabigerol (CBG): The “Mother” Cannabinoid
CBG is often called the “mother cannabinoid” because many other cannabinoids, including THC and CBD, are synthesised from its acidic precursor during plant development.
In vape formulations, CBG is gaining attention for its balancing qualities. Users describe it as clear and steadying, offering mental focus without stimulation. For daytime use, it pairs well with CBD, creating blends that support calm concentration rather than heavy relaxation.
Because CBG occurs naturally in very small amounts, isolating it used to be expensive. With new cultivation techniques, higher-CBG hemp strains are making it more accessible.
Cannabichromene (CBC): The Quiet Contributor
lesser known than CBG, cannabichromene (CBC) has subtle yet intriguing potential. Early research suggests it may interact strongly with receptors beyond the classic cannabinoid pathways, hinting at unique roles in mood and balance.
In vape blends, CBC often functions as a supporting note rather than a dominant feature. Think of it as part of the “entourage effect,” where multiple cannabinoids work together to shape the overall feel of a formulation.
Although vapes may not mention CBC content, it is present in most full-spectrum and broad-spectrum vapes. In future vapes, CBC amount may be higher, as science learns more about minor cannabinoids.
Cannabinol (CBN): Rest and Nighttime Use
CBN emerges when THC oxidises over time. Unlike THC, it is not strongly psychoactive. Instead, it is associated with gentle relaxation. Many users find it particularly suitable for evening routines.
Some low THC vape pens now highlight CBN as a selling point, pairing it with calming terpenes such as myrcene or linalool. The idea is to craft cartridges tailored for a higher stress relief effect—a natural fit for those seeking support with sleep hygiene or nighttime relaxation.
Tetrahydrocannabivarin (THCV): The Wild Card
THCV is structurally similar to THC but behaves differently in the body. At low doses, it appears to interact with cannabinoid receptors in a way that dampens appetite and promotes alertness. At higher doses, which are not relevant in UK-legal low THC products, it may show mild psychoactivity.
In vape formulations, trace amounts of THCV are being explored as a complement to CBD and CBG.
Early adopters describe it as providing a sharper, cleaner feel—potentially useful for daytime blends. Its role is still emerging, but THCV demonstrates how complicated hemp chemistry can be.
Building the Next Generation of Low THC Vapes
The inclusion of minor cannabinoids reflects a broader industry shift of THC vape industry towards tailored experiences. Instead of one-size-fits-all pens, the market is moving toward blends designed for different times of day or wellness goals: clarity through CBG, calm through CBD and CBN, balance through CBC, and focus through THCV.
This shift also relies on science. Transparent Certificates of Analysis are essential, showing not only compliance with the under 1 mg THC limit but also the presence of these emerging cannabinoids.
Using minor cannabinoids with terpenes may boost their action. Thus, for example, using limonene with CBG, or myrcene with CBN, creates combinations that feel distinct.
Challenges and Opportunities
Minor cannabinoids present challenges. Because they occur in small quantities, extraction can be a costly process. Demand is still evolving, so brands must strike a balance between innovation and affordability.
Legal clarity also matters; while CBD is widely accepted, some cannabinoids exist in regulatory grey zones.
Still, the opportunity is vast. By moving beyond CBD and THC, the industry can demonstrate that hemp’s potential is broader, more versatile, and more interesting than consumers may have imagined.
The Bottom Line
Low THC vapes in the UK no longer need to be limited to the familiar duo of CBD and THC. With cannabinoids like CBG, CBC, CBN, and THCV entering the picture, formulations are becoming more diverse, targeted, and engaging.
By exploring these emerging cannabinoids, the industry can provide better vapes fit for various requirements.
